Geode Capital Management
ADIL

Geode Capital Management’s Adial Pharmaceuticals ADIL Stock Holding History

Geode Capital Management’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.7K Sell
12,393
-11,856
-49% -$23.5K ﹤0.01% 4314
2026
Q1 		$43.4K Buy
24,249
+18,019
+289% +$63.4K ﹤0.01% 4347
2025
Q4 		$34.3K Sell
6,230
-335
-5% -$2.71K ﹤0.01% 4302
2025
Q3 		$58K Buy
6,565
+3,811
+138% +$37.1K ﹤0.01% 4258
2025
Q2 		$20.8K Hold
2,754
– – ﹤0.01% 4356
2025
Q1 		$43.7K Buy
2,754
+280
+11% +$5.78K ﹤0.01% 4224
2024
Q4 		$62.5K Buy
2,474
+655
+36% +$17K ﹤0.01% 4203
2024
Q3 		$45.4K Buy
1,819
+784
+76% +$20.4K ﹤0.01% 4283
2024
Q2 		$29.8K Buy
+1,035
New +$39.1K ﹤0.01% 4391
2023
Q3 		– Sell
-220
Closed -$28.6K – 4759
2023
Q2 		$28.6K Hold
220
– – ﹤0.01% 4607
2023
Q1 		$48.1K Hold
220
– – ﹤0.01% 4529
2022
Q4 		$29K Hold
220
– – ﹤0.01% 4709
2022
Q3 		$48K Buy
220
+3
+1% +$1.35K ﹤0.01% 4772
2022
Q2 		$182K Buy
217
+1
+0.5% +$906 ﹤0.01% 4323
2022
Q1 		$271K Buy
216
+9
+4% +$12.3K ﹤0.01% 4226
2021
Q4 		$349K Buy
207
+53
+34% +$104K ﹤0.01% 4224
2021
Q3 		$412K Buy
154
+13
+9% +$27.2K ﹤0.01% 4119
2021
Q2 		$225K Buy
141
+16
+13% +$24.3K ﹤0.01% 4302
2021
Q1 		$188K Hold
125
– – ﹤0.01% 4131
2020
Q4 		$132K Hold
125
– – ﹤0.01% 4006
2020
Q3 		$173K Hold
125
– – ﹤0.01% 3759
2020
Q2 		$108K Hold
125
– – ﹤0.01% 3828
2020
Q1 		$101K Hold
125
– – ﹤0.01% 3763
2019
Q4 		$187K Hold
125
– – ﹤0.01% 3817
2019
Q3 		$116K Hold
125
– – ﹤0.01% 3913
2019
Q2 		$131K Hold
125
– – ﹤0.01% 3892
2019
Q1 		$267K Buy
125
+103
+468% +$307K ﹤0.01% 3651
2018
Q4 		$69K Buy
+22
New +$35.2K ﹤0.01% 3932

Other funds holding ADIL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCM
Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management's ADIL Position: Q2 2026 in Review

Geode Capital Management reduced its Adial Pharmaceuticals (ADIL) stake by 49% in Q2 2026, selling an estimated $23.5K and leaving 12,393 shares worth $31.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4314.

Geode Capital Management first reported a position in ADIL in Q4 2018 and has held it in 28 quarters since. The position peaked at $412K in Q3 2021. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

  • Geode Capital Management held 12,393 shares of Adial Pharmaceuticals worth $31.7K as of Q2 2026.
  • Geode Capital Management sold 11,856 Adial Pharmaceuticals shares in Q2 2026, an estimated $23.5K.
  • Adial Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4314 holding.
  • Geode Capital Management first reported a position in Adial Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
  • Geode Capital Management's Adial Pharmaceuticals position peaked at $412K in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.